| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5582048 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 16 Pages |
Abstract
Our results lead us to conclude that generic imatinib as second-line therapy does not have deleterious effects on patient outcomes. However, first-line generic imatinib showed suboptimal efficacy compared with branded imatinib.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric, Amina Kurtovic-Kozaric,